



IDSAs

Infectious Diseases Society of America

2014-2015 BOARD OF DIRECTORS

President
Stephen B. Calderwood, MD, FIDSA
MASSACHUSETTS GENERAL HOSPITAL
BOSTON, MA

President-Elect
Johan S. Bakken, MD, PhD, FIDSA
ST. LUKE'S ID ASSOCIATES
DULUTH, MN

Vice President
William G. Powderly, MD, FIDSA
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
ST. LOUIS, MO

Secretary
Penelope H. Dennehy, MD, FIDSA
HASBRO CHILDREN'S HOSPITAL
PROVIDENCE, RI

Treasurer
Cynthia L. Sears, MD, FIDSA
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
BALTIMORE, MD

Immediate Past President
Barbara E. Murray, MD, FIDSA
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
HOUSTON, TX

Judith A. Aberg, MD, FIDSA
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
NEW YORK, NY

**Barbara D. Alexander, MD, MHS,
FIDSA**
DUKE UNIVERSITY MEDICAL CENTER
DURHAM, NC

R. Michael Buckley, MD, FIDSA
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
PHILADELPHIA, PA

Deborah Cotton, MD, MPH, FIDSA
BOSTON UNIVERSITY SCHOOL OF MEDICINE
BOSTON, MA

Janet A. Englund, MD, FIDSA
SEATTLE CHILDREN'S HOSPITAL
SEATTLE, WA

Thomas Fekete, MD, FIDSA
TEMPLE UNIVERSITY MEDICAL SCHOOL
PHILADELPHIA, PA

Lawrence P. Martinelli, MD, FIDSA
COVENANT HEALTH
LUBBOCK, TX

Louis B. Rice, MD, FIDSA
WARREN ALPERT MEDICAL SCHOOL
OF BROWN UNIVERSITY
PROVIDENCE, RI

Steven K. Schmitt, MD, FIDSA
CLEVELAND CLINIC
CLEVELAND, OH

Chief Executive Officer
Mark A. Leasure

IDSAs Headquarters
1300 Wilson Boulevard
Suite 300
Arlington, VA 22209
TEL: (703) 299-0200
FAX: (703) 299-0204
EMAIL ADDRESS:
info@idsociety.org
WEBSITE:
www.idsociety.org

December 10, 2014

The Honorable Michael Bennet
458 Russell Senate Office Building
Washington, DC 20510

The Honorable Orrin Hatch
104 Hart Senate Office Building
Washington, DC 20510

Dear Senators Bennet and Hatch:

I write to express the Infectious Diseases Society of America's (IDSAs) support for the Promise for Antibiotics and Therapeutics for Health (PATH) Act, legislation to establish a new limited population antibacterial drug approval pathway for antibacterial drugs to treat serious or life-threatening infections where there exists an unmet medical need. IDSAs greatly appreciates your leadership in authoring this important bill, and we are deeply concerned that without it, the new drugs our patients desperately need in order to stay alive will not be developed and brought to market.

IDSAs represents over 10,000 infectious diseases physicians and scientists devoted to patient care, prevention, public health, education, and research in the area of infectious diseases. Our members care for patients of all ages with serious infections, including meningitis, pneumonia, tuberculosis, HIV/AIDS, antibiotic-resistant bacterial infections such as those caused by methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), multidrug-resistant *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, and emerging infections such as that caused by the 2009 H1N1 influenza virus.

IDSAs is advocating for federal policies to revitalize antibiotic research and development (R&D) because more and more of our patients are dying from drug resistant infections and we have far too few, in some cases no, safe and effective therapies to treat them. A 2013 IDSAs report identified only seven new drugs in development for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (GNB), and none of these drugs addresses the complete set of needs associated with these infections.

In September, the President's Council of Advisors on Science and Technology (PCAST) issued a Report to the President on Combating Antibiotic Resistance that explicitly recommended the enactment of legislation to authorize the Food and Drug Administration (FDA) to establish a new approval pathway for antibiotics to be used in limited populations of patients. The PATH Act would implement this important

recommendation and speed patient access to important antibacterial drugs to treat serious or life-threatening infections where there exists an unmet medical need. The PATH Act would allow such drugs to be approved based upon smaller, more rapid clinical trials. It is often not feasible for these antibiotics to be developed using traditional, large clinical trials due to the limited numbers of patients in whom the targeted infections currently occur.

It is important that drugs approved under this pathway be used judiciously, particularly given that they will be approved for limited populations, not the broader population of patients with non-serious infections that can be treated effectively with existing drugs. Appropriate use is critical to deliver optimal patient care and protect these precious drugs from the development of resistance. IDSA strongly supports provisions in your legislation to help guide appropriate use, including clear labeling of drugs approved under this pathway (through a logo or other such means), pre-review of marketing materials, and monitoring the use of drugs approved under this pathway, as well as patterns of resistance.

IDSA greatly appreciates your commitment to strengthening patient care by reinvigorating the antibiotic pipeline. We are extremely pleased to work with you to advance the PATH Act.

Sincerely,

A handwritten signature in purple ink that reads "Stephen B. Calderwood". The signature is written in a cursive, slightly slanted style.

Stephen B. Calderwood, MD, FIDSA
President